Citi lowered the firm’s price target on Integra LifeSciences (IART) to $11 from $12 and keeps a Sell rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Integra Lifesciences Faces Revenue Shortfall and Lowered Outlook Amid Supply Chain Challenges
- Integra LifeSciences Reports Strong Q3 2025 Results
- Midday Fly By: Big Tech reports, Novo tops Pfizer bid for Metsera
- Integra LifeSciences sees Q4 EPS 79c-84c, consensus 92c
- Integra LifeSciences reports Q3 adjusted EPS 54c, consensus 43c